Use Of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) For Acute Musculoskeletal Pain In The Global Musculoskeletal Drugs Market (Companies Included: F. Hoffmann-La Roche Ltd., GlaxosmithKline Plc, Pfizer Inc., Abbott Laboratories Inc., Daiichi Sankyo Company, Limited)

The musculoskeletal system drugs market comprises companies that discover, develop, manufacture and distribute medications used in the treatment of musculoskeletal diseases. Musculoskeletal diseases include arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus and others. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

Read more:

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorders-drugs-global-market-report-2018

The global musculoskeletal drugs market has shown high growth in the past years with a CAGR of over 7.3%. The year 2017 recorded a net market value of $130 billion as per TBRC’s in-house consultants.

TBRC’s latest report show the historic and future trends in the market for each year with sourced reasons to support the growth claims.

The report also shows the global musculoskeletal drugs market to grow at a higher CAGR by 2021 as compared to 2017, along with geographies best suited for investments with highest return rate.

Sample report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=278&type=smp

 Topical NSAIDs are being used for treatment of acute musculoskeletal pain in adults. A NSAID penetrates the skin, enters tissues or joints, and reduces processes causing pain in the tissue. It can be used as a gel, cream, spray, or plaster to unbroken skin with musculoskeletal pain. Topical NSAIDs also leads to very low level of drug in the blood as compared to oral drugs, thus, minimizing the risk of harmful effects. In June 2015, medical research organization Cochrane published the results of its clinical trials to compare topical NSAIDs with placebo or other medicines in patients above 16 years with musculoskeletal pain. These results indicate that gel formulations of NSAIDs diclofenac and ketoprofen were more effective in treatment of strain, sprain, or muscle pull, as compared to placebo

Request for Discount: https://www.thebusinessresearchcompany.com/sample.aspx?id=278&type=discount

Companies included in the report are F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Abbott Laboratories Inc., and Daiichi Sankyo Company, Limited.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained 

researchers in 15 countries globally.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company

Global Musculoskeletal Drugs Market Is Expected To Grow To $177 Billion By 2021 According To TBRC’s Latest Report

The musculoskeletal system drugs market comprises companies that discover, develop, manufacture and distribute medications used in the treatment of musculoskeletal diseases. Musculoskeletal diseases include arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus and others. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer.

Read the report at

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorders-drugs-global-market-report-2018

The substantial reason for the growth of the musculoskeletal system drugs market from $130 billion in 2017 to $177 billion in 2021. This can be attributed to the expected increase in healthcare awareness, number of surgical operations and prevalence of musculoskeletal disorders such as fibromyalgia, rheumatoid arthritis, osteoarthritis around the world.  Also, increasing number of road accidents and workplace injuries are expected to contribute to market growth. 

 North America was the largest region in the musculoskeletal disorders drugs market in 2017, accounting for almost one-third of the market share.

The market is segmented into: drugs for rheumatoid arthritis, muscle relaxants and others.

Download a sample of the report at

https://www.thebusinessresearchcompany.com/sample.aspx?id=257&type=smp

The USA was the largest country in the musculoskeletal disorders drugs market in 2017, accounting for almost one-sixth of the market share. This can be attributed to the increasing old age population and high per capita healthcare expenditure compared to other countries. The USA was followed by Japan and China.

The top five competitors in the market made up nearly 10% of the total market in 2017. F. Hoffmann-La Roche Ltd. was the largest competitor followed by GlaxosmithKline Plc., Pfizer Inc., Abbott Laboratories Inc. and Daiichi Sankyo Company Limited. F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The company headquarters are located in Basel.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Drugs To Treat Metabolic Disorders Present The Best Opportunities For Pharma Companies, Says TBRC

The fastest-growing segment of the global pharma market to 2021 will be in drugs for treating metabolic disorders such as diabetes and disorders of the thyroid and pituitary gland, a report from The Business Research Company shows. This market will grow at 9% a year going forward, following recent growth of 11.6%, but it will remain in fifth place for market size behind the musculoskeletal, cardiovascular, oncology and anti-infective drug markets. Drugs to treat diabetes account for over 97% of the global metabolic pharma market.

The USA has by far the largest market for metabolic disorder drugs, worth $29.9 billion in 2017, and it is there that the segment accounts for the largest share of the market, at 12.8%. These drugs are also a significant part of the much smaller Indian market, at 8.8% of total pharma sales in the country.

Read More: https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report-2018

The pharmaceutical drugs industry develops drugs to diagnose, cure, treat or prevent metabolic diseases. Global population aging, the obesity crisis, growing awareness of diseases like diabetes, and, in the emerging economies, increasing affordability of treatment, help explain the rapid growth of the metabolic drugs market.

The global pharma market as a whole was worth $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%, an accelerated pace compared to 5.2% for the years before 2017.

North America (the USA, Canada, and Mexico) is the largest regional market for the pharma companies, worth $341 billion in 2017; Asia Pacific is in second place with $200 billion of annual sales. Growth has been and will continue to be spread across all regions of the world, though faster in some than others. North America's growth will be only 5.1% a year, below the global average, while Asia Pacific's will be the highest globally at 8.4% per annum. Western Europe is expected to have the lowest annual growth rate of 3.9% from 2017 to 2021. Its share in the global market in 2017 was 19.4%, worth $180.9 billion.

Request Sample: https://www.thebusinessresearchcompany.com/sample.aspx?id=777&type=smp

Pharmaceutical companies produce both generic and branded drugs. Pharmaceutical drugs are subject to a number of laws and regulations that deal with patenting, testing, safety, efficacy and marketing and affect the size and growth rates of the market. Pharmaceutical companies produce pharmaceutical drugs made from active pharmaceutical ingredients (API) and excipients.

The leading pharma companies are Swiss company Novartis, with just under 5% of the global market in 2017, followed by Sanofi, which is French, then Hoffmann-La Roche, Swiss again. The top ten pharmaceutical manufacturers shared a little over 30% of the global market between them.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293 Email: info@tbrc.info

Brazil, Russia And India Offer The Best Opportunities In The Musculoskeletal Drugs Markets To 2020

Three of the BRICs (Brazil, Russia and India) have high recent and forecast market growth rates for musculoskeletal drugs and so will move up the table of consumer countries for these drugs. Currently the largest markets for drugs that treat diseases such as arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome and muscular dystrophy are in countries such as the USA and Japan and China; the USA's market is and will remain vastly bigger than any other, but the three BRIC markets are beginning to catch up with Japan and China. For example, while India's market was only two-thirds of Japan's in 2016, by 2020 its sales will be equal to 84% of the Japanese sales. Again, Again, Brazil's market was only half as big as China’s in 2016 but will be worth nearly 60% of that market by 2020. 

Many musculosketal disorders are incurable so that patients will take these pain- and inflammation-reducing drugs either continuously or periodically for life. As their incidence is age-related, the increase in the size of the aging population is one factor driving the growth of this market. Other factors are increasing global obesity and stress levels.

Globally, the market for musculosketal drugs equates to about 14% of the pharma total and is growing at over 7% year on year. This compares with growth rates around 5% for pharmaceuticals in general.

The benefits of growth in these markets will be widely distributed. Although the leading manufacturers of these drugs are the Swiss company Hoffmann-La Roche, the British GlaxoSmithKline and the USA’s Pfizer, the top ten pharma companies together only account for around 10% of global sales. Small pharma companies in the emerging economies and generic drugs account for the majority of sales of these products.

Where to Learn More
Read Musculoskeletal Disorders Drugs Global Market Report 2018 from The Business Research Company for information on the following:

Markets Covered: Rheumatoid Arthritis, Muscle Relaxants, Others
Companies Mentioned: AbbVie, Amgen, Johnson & Johnson, F. Hoffmann-La Roche Ltd, and Pfizer Inc.
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293 Email: info@tbrc.info